The Division of Gastroenterology & Hepatology at Warren Alpert Medical School of Brown University is located at Rhode Island and Miriam Hospitals and the Veteran’s Administration Medical Center. The Liver Research Center is a 13,000 square foot facility located at 55 Claverick Street, half a mile from Rhode Island Hospital. The major missions of the Division are to provide state-of-the-art treatment for patients with gastrointestinal and liver diseases, to educate undergraduates, medical students, medical residents and postdoctoral fellows in the pathophysiology of digestive diseases and to provide a strong basic science program for advancing the understanding of these disease processes at the cellular and molecular level.
The clinical program is robust and serves as a focus for translational research activities. Currently, there are 27 active research studies. We also offer the opportunity to understand GI and liver diseases in a broader global context with our international program which allows for a one-month rotation in one of 18 sites throughout the world. This opportunity is offered in the third year of fellowship training. The Division also provides a training track in GI and liver diseases in women, including pregnancy.
Overall, the activities of the Division allow for career development opportunities in clinical gastroenterology and hepatology, as well as basic and translational research in digestive diseases with the opportunity to be involved at all levels of the educational process.
Research Update – Digestive Disease Week, May 2022
Congratulations to our fellows (aided by residents) and faculty who presented their research in San Diego. Listed below are the 14 presentations from our GI faculty (in bold). fellows and residents (underlined).
Click here to reveal the full list of presentations...
1. PREDICTORS AND OUTCOMES OF USTEKINUMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE. Authors: Petrov JC, Fine S, Al Bawardy B.
2. HELICOBACTER PYLORI ANTIMICROBIALS RESISTANCE AND ERADICATION IN AFRICA: A SYSTEMIC REVIEW. Authors: Chukwudike ES, Asombang AW, Sawyer K, Egboh SMC, Tazinkeng NN, Pearlstein E, Oyeleke GK, Nowbuth AA, Argueta E, Moss SF.
3. LOCATION MATTERS: OUTCOMES OF ENDOSCOPIC RETROGRADECHOLANGIOPANCREATOGRAPHY IN THE ENDOSCOPY UNIT VERSUS THE OPERATING ROOM. Authors: Cho J, Marino D, Monteiro JFG, Kalligeros M, Egger K, Akerman P, Habr F, Hyder S.
4. OUT WITH THE OLD, IN WITH THE NEW: TWO YEAR FOLLOW-UP OF PRACTICE PATTERNS AND COMPLIANCE WITH PLASTIC BILIARY STENT MANAGEMENT. Authors: Kothadia S, Min M, Monteiro JFG, Jamot S, Hyder S.
5. OPTIMIZATION OF A PROGRAMMATIC MAILED FECAL IMMUNOCHEMICAL TEST INITIATIVE FOR COLORECTAL CANCER SCREENING IN THE ERA OF COVID-19. Authors: Min M, Ouellette J, Egger K, Pearlstein E, Myers T, Shittu Y, Promrat K.
6. LIVER INJURY IN HOSPITALIZED COVID-19 PATIENTS TREATED WITH TOCILIZUMAB. Authors: Kalligeros M, Shehadeh F, Kothadia S, Marino D, Mylona E, Wands JR, Mylonakis E.
7. CHOLEDOCHOLITHIASIS CAN PRESENT WITH EXTREME TRANSAMINASE ELEVATION: A SYSTEMATIC REVIEW AND META-ANALYSIS. Authors: Mohamed M, Marino M, Farrakhan K, Farrell R.
8. ANTICIPATED IMPACT OF LIVE BIOTHERAPEUTIC PRODUCTS ON FECAL MICROBIOTA TRANSPLANTATION (FMT) PRACTICE. AUTHORS: Sharen J, Kim AM, Fredell L, Nersesova Y, Serra SM, Lewis JD, Wu GD, Laine L, Kelly CR.
9. PRE-FMT ANTIBIOTIC USE IS ASSOCIATED WITH HIGHER RATES OF CURE AFTER FECAL MICROBIOTA TRANSPLANTATION FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION. Authors: Yen EF, Kelly CR, Chiou I, Amusin DB, Serra SM, Nersesova Y, Fredell L, Laine L.
10. CP101, AN INVESTIGATIONAL ORALLY ADMINISTERED MICROBIOME THERAPEUTIC, WAS EFFECTIVE FOR PREVENTION OF RECURRENT C. DIFFICILE INFECTION: RESULTS FROM OPEN-LABEL PRISM-EXT TRIAL. Authors: Allegretti JR, Kelly CR, Fischer M, Cohen T, Gerardin Y, Budree S, Khanna S.
11. GLOBAL TEMPORAL TRENDS IN THE EFFICACY OF CLARITHROMYCIN-CONTAINING REGIMENS IN HELICOBACTER PYLORI ERADICATION. Authors: Moss S, Chey, WD, Daniele P, Pelletier C, Jacob R, Tremblay G, Hubscher E, Malfertheiner P.
12. COMPARATIVE EFFICACY OF ACID SUPPRESSION BACKBONES FOR HELICOBACTER PYLORI ERADICATION: RESULTS OF A NETWORK META-ANALYSIS. Authors: Malfertheiner P, Moss S, Daniele P, Pelletier C, Jacob R, Tremblay G, Hubscher E, Chey WD
13. COMPARATIVE EFFICACY OF HELICOBACTER PYLORI ERADICATION THERAPIES: A NETWORK META-ANALYSIS. Authors: Malfertheiner P, Moss S, Daniele P, Pelletier C, Jacob R, Tremblay G, Hubscher E, Chey WD
14. DIAGNOSTIC AND TREATMENT PRACTICES FOR HELICOBACTER PYLORI INFECTION IN AN ACADEMIC PEDIATRIC HOSPITAL. Authors: Riaz MS, Moss S, Zonfrillo M, Koby K, Herzlinger M.